BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Latest Information Update: 27 Dec 2024
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Hypertrophy
- Focus Adverse reactions; Therapeutic Use
- Sponsors AbbVie
Most Recent Events
- 24 Dec 2024 Status changed from recruiting to active, no longer recruiting.
- 16 Dec 2024 Planned End Date changed from 21 Dec 2025 to 1 Dec 2025.
- 16 Dec 2024 Planned primary completion date changed from 21 Dec 2025 to 1 Dec 2025.